X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ANGN

Closed

Angion Biomedica Corp

1.
0 (0.00%)
Last Update: 01 Jun 2023 23:00:00
Yesterday: 1.
Day's Range: 0. - 0.
Send
When Written:
 
0.58
Angion Biomedica Corp is a clinical-stage biopharmaceutical company that focuses on developing novel therapies for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a small-molecule hepatocyte growth factor mimetic that is being developed for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD). ANG-3777 has completed Phase 2 clinical trials for AKI and is currently in Phase 3 clinical trials for the same indication.

Angion Biomedica Corp was founded in 2008 and is headquartered in Uniondale, New York. The company's mission is to improve the lives of patients suffering from acute organ injuries and fibrotic diseases through the development of innovative therapies. Angion Biomedica Corp is publicly traded on the NASDAQ stock exchange under the ticker symbol ANGN.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X